Clinical trial: immuno-PET optimization protocol
Immuno-PET optimization protocol: anti-ACE pre-targeting
Type of study: Feasibility study
Pathology: HER2 negative, ACE positive metastatic breast cancer
Investigator : Pr. Francoise Kraeber Bodéré
NCT number: NCT01730612
The aim of this trial was to evaluate a new imaging technique: Immuno PET (i PET) using a tumour specific target: 68Ga labelled anti-ACE antibody, using a pre-targeting technique. These results were compared to standard imaging techniques: FDG PET (glucose analogue), CT and MRI of the spine.
The study showed that anti-ACE PET was more sensitive in detecting metastases than the gold standard (or reference test). This includes brain metastases, which are poorly or not at all visible on FDG PET due to brain background. This potential molecular imaging technique, known as companion imaging, would allow assessment of CEA expression on a whole-body basis, including lesions not accessible by biopsy.
Publication : This study was concluded and published in the JNM in March 2020